PMID- 23128843
OWN - NLM
STAT- MEDLINE
DCOM- 20130117
LR  - 20220309
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 84
IP  - 1
DP  - 2013
TI  - Mammalian target of rapamycin as a rational therapeutic target for breast cancer 
      treatment.
PG  - 43-56
LID - 10.1159/000343063 [doi]
AB  - Therapies directed at endocrine receptors and human epidermal growth factor 
      receptor 2 are important treatment options for patients with breast cancer; 
      however, drug resistance and subsequent disease progression in patients with 
      advanced disease is inevitable. The mammalian target of rapamycin (mTOR) is a key 
      regulator of cell growth and proliferation implicated in the cellular processes 
      that lead to the uncontrolled growth of cancer cells. Hence, overactivation of 
      the mTOR pathway may also represent a key process in the development of 
      resistance to these therapies, and interrupting this signaling cascade may 
      alleviate resistance and help restore drug sensitivity. A number of agents that 
      target the mTOR pathway have shown potent antitumorigenic effects in vitro, and 
      several agents have also shown promise in treating patients with breast cancer. 
      Everolimus and temsirolimus are the most clinically advanced agents in this 
      class, with recent data from the BOLERO-2 study indicating significant benefit 
      associated with everolimus when added to endocrine therapy in patients with 
      endocrine therapy-resistant disease. In this review, we consider the translation 
      of mTOR inhibitors from laboratory studies to large clinical trials, driven by a 
      rational understanding of the role of mTOR in the processes that underlie breast 
      cancer tumorigenesis.
CI  - Copyright (c) 2012 S. Karger AG, Basel.
FAU - LoRusso, Patricia Mucci
AU  - LoRusso PM
AD  - Karmanos Cancer Institute/Wayne State University, Detroit, MI 48201, USA. 
      lorussop@karmanos.org
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20121030
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/metabolism
MH  - Female
MH  - Humans
MH  - Prognosis
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
EDAT- 2012/11/07 06:00
MHDA- 2013/01/18 06:00
CRDT- 2012/11/07 06:00
PHST- 2012/03/01 00:00 [received]
PHST- 2012/08/27 00:00 [accepted]
PHST- 2012/11/07 06:00 [entrez]
PHST- 2012/11/07 06:00 [pubmed]
PHST- 2013/01/18 06:00 [medline]
AID - 000343063 [pii]
AID - 10.1159/000343063 [doi]
PST - ppublish
SO  - Oncology. 2013;84(1):43-56. doi: 10.1159/000343063. Epub 2012 Oct 30.